News

IMI-money for intelli-research
Enlarge image

FundingEUUKSwitzerland

IMI-money for intelli-research

06.12.2012 - The Innovative Medicines Initiative funds seven new projects with a total of €237m. The main focus is on drug development and data integration.

The exciting field of stem cell research and the seemingly insurmountable ranges of biodata are undergoing in-depth analyses over the next few years. The unifying context behind these projects is the mission to improve drug development. As announced on 5 December, the Innovative Medicines Alliance (IMI) will spend in total more than €237m on research topics ranging from stem cells (STEMBANCC), data integration (EMIF and eTRIKS) and ‚green’ drug development (CHEM21) to drug-target-interaction (K4DD), drug uptake into (ORBITO) and drug distribution within (COMPACT) the body.

Within STEMBANCC ten pharmaceutical companies and 23 academic institutions from 11 countries will develop 1,500 human induced pluripotent stem cell lines from about 500 patients to study diseases and test drugs for safety and efficacy. Swiss pharma Roche initiated the project, which will be coordinated by the University of Oxford (UK). Using cells isolated from patients, the scientists hope to identify the genes and mechanisms that play a role in diseases of the nervous system such as peripheral pain, migraine, autism, schizophrenia, bipolar disorders, dementiae and diabetes. Taken together, IMI now finances 37 projects with a volume of almost €800m.

It was just in June this year, that the last current IMI projects were presented. The €215m they received is only 91% of the sum the new projects of the 4th wave will get. The IMI, a joint venture of the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) is Europe’s biggest public-private partnership to accelerate the development of better drugs. Currently, applicants can bid for the 8th call „Combating Antibiotic Resistance“. The calls five to seven have already been closed for submission of Expressions of Interest (EoI) and are in different stages of processing.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/imi-money-for-intelli-research.html

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SANTHERA80.00 CHF6.74%
  • WILEX2.26 EUR1.80%
  • ADDEX4.07 CHF1.75%

FLOP

  • MOLOGEN7.30 EUR-6.41%
  • 4SC1.16 EUR-3.33%
  • EVOLVA1.27 CHF-2.31%

TOP

  • MAGFORCE6.47 EUR19.8%
  • SANTHERA80.00 CHF15.1%
  • LONZA101.50 CHF9.7%

FLOP

  • WILEX2.26 EUR-31.1%
  • MOLOGEN7.30 EUR-22.8%
  • VITA 343.79 EUR-19.9%

TOP

  • SANTHERA80.00 CHF3802.4%
  • CO.DON2.50 EUR228.9%
  • PAION2.41 EUR186.9%

FLOP

  • CYTOS0.27 CHF-93.3%
  • MEDIGENE4.60 EUR-66.4%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 20.08.2014